Abstract
Enveloped animal viruses fuse their membrane with a host cell membrane in order to deliver their genome into the cytoplasm of the cell and thus initiating infection. This crucial step is mediated by virally encoded transmembrane proteins that, following an appropriate triggering, insert their fusion peptides into the target membrane and, through a cascade of conformational changes, drive the merging of the two apposing membranes. The battle against viruses is ongoing with the constant threat of viruses developing resistance to present drugs and emerging viruses, therefore there is a continuous challenge to improve our defence strategies. Entry inhibitors are currently in development for diverse human and animal viral pathogens, and advances in our understanding on how viral entry proteins undergo conformational changes that lead to entry offer a huge potential for the development of novel therapeutics. This review describes recent advances on viralmediated fusion mechanisms concentrating on the development of peptidic inhibitors of membrane fusion.
Keywords: Membrane fusion, viral fusion peptide, viral inhibitor, heptad repeat, fusion peptide, glycoprotein
Protein & Peptide Letters
Title: Inhibition of Viral-Induced Membrane Fusion by Peptides
Volume: 16 Issue: 7
Author(s): Mariaterasa Vitiello, Marilena Galdiero and Massimiliano Galdiero
Affiliation:
Keywords: Membrane fusion, viral fusion peptide, viral inhibitor, heptad repeat, fusion peptide, glycoprotein
Abstract: Enveloped animal viruses fuse their membrane with a host cell membrane in order to deliver their genome into the cytoplasm of the cell and thus initiating infection. This crucial step is mediated by virally encoded transmembrane proteins that, following an appropriate triggering, insert their fusion peptides into the target membrane and, through a cascade of conformational changes, drive the merging of the two apposing membranes. The battle against viruses is ongoing with the constant threat of viruses developing resistance to present drugs and emerging viruses, therefore there is a continuous challenge to improve our defence strategies. Entry inhibitors are currently in development for diverse human and animal viral pathogens, and advances in our understanding on how viral entry proteins undergo conformational changes that lead to entry offer a huge potential for the development of novel therapeutics. This review describes recent advances on viralmediated fusion mechanisms concentrating on the development of peptidic inhibitors of membrane fusion.
Export Options
About this article
Cite this article as:
Vitiello Mariaterasa, Galdiero Marilena and Galdiero Massimiliano, Inhibition of Viral-Induced Membrane Fusion by Peptides, Protein & Peptide Letters 2009; 16 (7) . https://dx.doi.org/10.2174/092986609788681742
DOI https://dx.doi.org/10.2174/092986609788681742 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immuno - Functionalized Silver Nanoparticles for Diagnostics, Therapeutics and Protection of Rabies Viral Infection
Current Nanomedicine Editorial: [Hot Topic HIV and Substance Abuse]
Current HIV Research Drugs Targeting Parasite Lysosomes
Current Pharmaceutical Design Is there a Teratogenicity Risk Associated with Cannabis and Synthetic Cannabimimetics’ (‘Spice’) Intake?
CNS & Neurological Disorders - Drug Targets Inflammation and Innate Immune Response Against Viral Infections in Marine Fish
Current Pharmaceutical Design Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Antiviral Herbs - Present and Future
Infectious Disorders - Drug Targets Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
CNS & Neurological Disorders - Drug Targets Epstein-Barr Encephalitis in a Child with Congenital Human Immunodeficiency Virus Infection: A Case Report Calling for No Forgetfulness
Current HIV Research Polymeric Aggregates in Ionic Liquids: the Green Future of the Delivery Systems
Current Drug Targets Tandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics
CNS & Neurological Disorders - Drug Targets Levamisole-Induced Leukoencephalopathy in Russia: Analysis of 30 Cases
Current Drug Safety Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Current Gene Therapy The Potential for Genetically Altered Microglia to Influence Glioma Treatment
CNS & Neurological Disorders - Drug Targets Multimodality Imaging in Acute Ischemic Stroke
Current Medical Imaging Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design Current Status of Anti-HIV Agents
Current Medicinal Chemistry - Anti-Infective Agents Mechanisms of HIV-1 Tat Neurotoxicity via CDK5 Translocation and Hyper-Activation: Role in HIV-Associated Neurocognitive Disorders
Current HIV Research